Decreased Survival of Subjects With Elevated Liver Function Tests During A 28-Year Follow-Up
Cecilia Söderberg, Per I Stal, Johan Askling et al. · Hepatology · 2009
UNLABELLED: The long-term survival of subjects with nonalcoholic fatty liver disease (NAFLD) in comparison with both individuals with elevated transaminases attributable to other causes and the general poulation is poorly characterized. This study was undertaken to determine the frequency of NAFLD in a cohort of subjects who underwent liver biopsy from 1980 to 1984 because of elevated liver enzymes, and to assess mortality among subjects with NAFLD in comparison with the general Swedish population. The 256 subjects (61% men) had a mean age of 45 +/- 12 years at the inclusion. Liver biopsies were blindly scored for NAFLD and nonalcoholic steatohepatitis (NASH). Causes of death were ascertained from the national Swedish Cause of Death Registry. Fatty liver was detected in 143 of the 256 subjects, including 25 (10%) with alcoholic fatty liver disease and 118 (46%) exhibiting NAFLD. Of those, 51 (20%) were classified as NASH and 67 (26%) as nonalcoholic bland steatosis. Cirrhosis was present in 9% at inclusion. During the follow-up period, 113 (44%) of the total population and 47 (40%) of the 118 subjects diagnosed with NAFLD died. Of the 113 deaths, 37 were of cardiovascular disease and 16 of liver diseases. Compared with the total Swedish population, adjusted for sex, age, and calendar period, subjects with NAFLD exhibited a 69% increased mortality (standardized mortality ratio [SMR] = 1.69; 95% confidence interval [CI], 1.24-2.25); subjects with bland steatosis, a 55% increase (SMR, 1.55; 95% CI, 0.98-2.32; P = 0.062); and subjects with NASH, 86% (SMR, 1.86; 95% CI, 1.19-2.76; P = 0.007). CONCLUSION: Patients with NASH are at increased risk of death compared with the general population. Liver disease is the third most common cause of death among patients with NAFLD.
Cited by 754 works. doi:10.1002/hep.23314 Open-access PDF
Authors
References
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
- Nonalcoholic Steatohepatitis
- Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
- Nonalcoholic steatohepatitis: An expanded clinical entity
- Estimating the world cancer burden: Globocan 2000
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
- Long‐term follow‐up of patients with NAFLD and elevated liver enzymes†‡
- Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma
- Liver Biopsy Interpretation
- An Update on Terminology and Reporting